Efficacy and Safety of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: Year 1 Interim Analysis of the ENLIGHTEN Study (P11-1.004)

Authors

Emily Riser (ORCID: https://orcid.org/0000-0002-0486-2594)
Thomas Leist (ORCID: https://orcid.org/0000-0002-8924-8891)
Ahmed Z. Obeidat (ORCID: https://orcid.org/0000-0002-3549-3277)
Massimiliano Cristofanilli
Sarah A. Morrow (ORCID: https://orcid.org/0000-0001-7522-6440)
John DeLuca (ORCID: https://orcid.org/0000-0003-3745-4156)
Robert T. Naismith (ORCID: https://orcid.org/0000-0003-0520-4283)
Ann Bass
Robert Zivadinov (ORCID: https://orcid.org/0000-0002-7799-1485)
Jon Riolo
Amanpreet Kaur (ORCID: https://orcid.org/0000-0002-5615-2666)
Mark Gudesblatt
James Appio

Institutions

Western University (CA)
Thomas Jefferson University (US)
Bristol-Myers Squibb (Germany) (DE)
University of Calgary (CA)
Medical College of Wisconsin (US)
Kessler Foundation (US)
London Health Sciences Centre (CA)
University at Buffalo, State University of New York (US)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000210399
Primary Topic: Multiple Sclerosis Research Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: Year 1 Interim Analysis of the ENLIGHTEN Study (P11-1.004)

Emily Riser, Thomas Leist, Ahmed Z. Obeidat, Massimiliano Cristofanilli et al.

Apr 7, 2025

Neurology

Multiple Sclerosis Research Studies

article

Efficacy and Safety of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: Year 1 Interim Analysis of the ENLIGHTEN Study (P11-1.004)

Emily Riser, Thomas Leist, Ahmed Z. Obeidat, Massimiliano Cristofanilli, Sarah A. Morrow, John DeLuca, Robert T. Naismith, Ann Bass, Robert Zivadinov, Jon Riolo, Amanpreet Kaur, Mark Gudesblatt, James Appio

April 7, 2025article en

Abstract

No abstract available for this paper.

NeurologyVol. 104(7_Supplement_1)

Western University (CA), Thomas Jefferson University (US), Bristol-Myers Squibb (Germany) (DE), University of Calgary (CA), Medical College of Wisconsin (US), Kessler Foundation (US), London Health Sciences Centre (CA), University at Buffalo, State University of New York (US)

Zero hunger

Openalex Percentile: Top 90%

Multiple Sclerosis Research Studies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and Safety of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: Year 1 Interim Analysis of the ENLIGHTEN Study (P11-1.004) — Emily Riser, Thomas Leist, et al. · Neurology (2025) | TGRS Research Map | TGRS